Modus Therapeutics AB is a Swedish drug development company developing sevuparin, which has the potential to restore blood flow in both sickle cell disease and malaria patients. Sevuparin originates from research at the Karolinska Institute and Uppsala University. A Phase II study is ongoing in Sickle Cell Disease.
View Top Employees from Modus Therapeutics AB| Website | https://www.modustx.com |
| Revenue | $6 million |
| Employees | 4 (2 on RocketReach) |
| Founded | 2011 |
| Phone | +46 70 790 02 07 |
| Technologies |
JavaScript,
HTML,
reCAPTCHA
+13 more
(view full list)
|
| Industry | Pharmaceuticals, Manufacturing General, Drug Delivery, Manufacturing, Drug Discovery |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Modus Therapeutics AB employee's phone or email?
Modus Therapeutics AB Questions
The Modus Therapeutics AB annual revenue was $6 million in 2024.
2 people are employed at Modus Therapeutics AB.
Modus Therapeutics AB is based in Stockholm, Stockholms Lan.
The NAICS codes for Modus Therapeutics AB are [32541, 32, 325, 3254].
The SIC codes for Modus Therapeutics AB are [28, 283].
Top Modus Therapeutics AB Employees
Related Companies
